Prime Medicine Inc. (NASDAQ:PRME) is one of the best biotech penny stocks to buy according to analysts. On December 23, LifeSci Capital initiated coverage of Prime Medicine with an Outperform rating and $6 price target. The firm highlighted that Prime Medicine is advancing one-and-done gene editing treatments for conditions with high unmet medical needs, specifically Wilson’s disease, alpha-1 antitrypsin deficiency/AATD, and cystic fibrosis. LifeSci Capital expressed particular optimism regarding the comme ...